MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
ARCA biopharma Total Shareholders Equity 2011-2026 | ABIO
Annual Total Shareholders Equity ARCA biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 382 M | 37 M | 41.7 M | 51 M | 46.5 M | 7.61 M | 6.03 M | 10.3 M | 22.2 M | 38.1 M | 14.7 M | 15.6 M | 2.91 M | 5.73 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 382 M | 2.91 M | 48.7 M |
Quarterly Total Shareholders Equity ARCA biopharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 487 M | 344 M | 365 M | 382 M | 342 M | -29 M | 35.1 M | 37 M | 38 M | 39.2 M | 40.5 M | 41.7 M | 42.7 M | 45 M | 47.9 M | 51 M | 56.6 M | 61.2 M | 65.9 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 7.61 M | 7.61 M | 7.61 M | 7.61 M | 6.03 M | 6.03 M | 6.03 M | 6.03 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 38.1 M | 38.1 M | 38.1 M | 38.1 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 2.91 M | 2.91 M | 2.91 M | 2.91 M | 5.73 M | 5.73 M | 5.73 M | 5.73 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 487 M | -29 M | 53.8 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
370 M | $ 20.2 | -2.42 % | $ 2.55 B |  USA |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 0.82 | -2.95 % | $ 4.47 M |  China |
 |
Axsome Therapeutics
AXSM
|
88.3 M | $ 166.57 | 0.11 % | $ 8.29 B | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.71 | -3.01 % | $ 1.11 B |  Canada |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 8.54 | -2.23 % | $ 1.4 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
22.6 M | $ 25.9 | -3.57 % | $ 694 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
66.9 M | $ 0.99 | -3.12 % | $ 72.7 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
954 M | $ 23.77 | -0.46 % | $ 2.91 B | USA |
 |
Agenus
AGEN
|
-160 M | $ 3.22 | -3.59 % | $ 1.15 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.19 B | $ 28.48 | -2.47 % | $ 1.65 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
38.7 M | $ 17.75 | -0.78 % | $ 852 M | USA |
 |
Champions Oncology
CSBR
|
3.77 M | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
309 M | $ 3.65 | -3.95 % | $ 116 M | France |
 |
Alector
ALEC
|
30.6 M | $ 2.11 | -4.75 % | $ 217 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
124 M | $ 4.16 | -0.12 % | $ 295 M | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
459 M | $ 14.12 | 1.36 % | $ 5.86 B |  Irlanda |
 |
AbbVie
ABBV
|
-3.27 B | $ 233.46 | -0.32 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
299 M | - | - | $ 8.14 B | USA |